Botanix Investor Centre

Botanix is an ASX-listed company (ASX:BOT), in a prime position for growth and to return value for shareholders. With deep expertise in dermatology and pharmaceutical product commercialisation, we are on track to disrupt some of the most lucrative global healthcare markets.

ASX: BOT | Share price


Feb 4, 2021
April 6, 2017
12 July 2022
December 9, 2019
September 17, 2019
January 31, 2019
November 15, 2018
August 13, 2018
April 9, 2018
November 13, 2017

Latest video

Analyst Report | 6 April 2023

Euroz Hartleys has published an analyst note, reporting on the…

Botanix secures commitments for A $10 million via institutional placement

Botanix lifted a trading halt this morning, sharing news that…

Mid-Cycle Review Complete + Capital Raise

Botanix has today released an update regarding the progress…

Investor Webinar | March 2023

Botanix (ASX: BOT) hosted a webinar to update shareholders on…

Special Report | Stockhead

Botanix has today appeared in Stockhead in an article titled,…

Botanix co-founder says interest for sweat-stopper gel is keeping him bullish ahead of FDA review | The West Australian

Botanix’s co-founder and Executive Director, Matt Callahan,…

Analyst Report by Euroz Hartleys – 01 February 2023

Euroz Hartleys has published an analyst note, reporting that…

Check out our latest investor presentation

Sign up to receive our latest news

Thank you! Your subscription has been confirmed. You'll hear from us soon.